Centre For Training In Clinical Cardiovascular And Cerebrovascular Research
Funder
National Health and Medical Research Council
Funding Amount
$2,000,000.00
Summary
This Centre proposes to expand its highly successful Centre of Clinical Excellence funded by NHMRC from 1998-2001. The Centre provided the opportunity in Western Australia for the highest quality clinical research training in comprehensive spheres relevant to the pathogenesis, prevention and therapeutics of cardiovascular disease, with an emphasis on the role of nutrition and lifestyle in relation to high blood pressure, arteriosclerosis, dyslipidaemia and the function of blood vessels. The new ....This Centre proposes to expand its highly successful Centre of Clinical Excellence funded by NHMRC from 1998-2001. The Centre provided the opportunity in Western Australia for the highest quality clinical research training in comprehensive spheres relevant to the pathogenesis, prevention and therapeutics of cardiovascular disease, with an emphasis on the role of nutrition and lifestyle in relation to high blood pressure, arteriosclerosis, dyslipidaemia and the function of blood vessels. The new Centre will broaden the scope of its research and training activities, through the inclusion of clinical projects related to heart failure, clinical and epidemiological research into cerebrovascular disease and stroke and research training opportunities with respect to clotting disorders and therapeutics for thrombosis.Read moreRead less
Formation, Structure And Metabolism Of High Density Lipoproteins Containing Both ApoAI And ApoAII On The Same Particle
Funder
National Health and Medical Research Council
Funding Amount
$296,884.00
Summary
It is well known that high levels of cholesterol in blood cause coronary heart disease. It is also known that not all of the cholesterol in blood is bad. Whereas the cholesterol carried in particles called low density lipoproteins (LDLs) causes heart disease, other cholesterol carriers in blood known as high density lipoproteins (HDLs) actually protect against the development of heart disease. However, HDLs include several different populations of particles, only some of which are protective. On ....It is well known that high levels of cholesterol in blood cause coronary heart disease. It is also known that not all of the cholesterol in blood is bad. Whereas the cholesterol carried in particles called low density lipoproteins (LDLs) causes heart disease, other cholesterol carriers in blood known as high density lipoproteins (HDLs) actually protect against the development of heart disease. However, HDLs include several different populations of particles, only some of which are protective. One determinant of the ability of HDLs to protect against coronary heart disease is their protein composition. This project investigates how the protein composition of HDL populations influences their structure, function and metabolism. It is also concerned with understanding what regulates the relative concentrations of the different HDL populations. The studies of HDL structure, function and metabolism will allow us to understand why the different HDL populations differ in their abilities to protect against heart disease. The regulation studies will tell us how to go about designing therapies to increase the levels of those HDL populations that do protect.Read moreRead less
Impact Of Advanced Glycation On Anti-atherogenic Properties Of High Density Lipoprotein
Funder
National Health and Medical Research Council
Funding Amount
$372,471.00
Summary
Type 2 diabetes is a rapidly growing medical problem in Australia and around the world. Diabetes affects human health through its complications and the cardiovascular complications are a cause for major concern. One of the complications is the effect on plasma lipids: it makes cholesterol carrying particles to accumulate in the blood vessels, causing atherosclerosis. We intend to investigate how diabetes modify these particles making them atherogenic.
Benefits Of Intravenous L-Carnitine Supplementation In Long-Term Haemodialysis Patients
Funder
National Health and Medical Research Council
Funding Amount
$406,648.00
Summary
Carnitine allows the body to utilise fats in our diet, permitting normal functioning of the body. The applicants have shown that patients who receive long-term haemodialysis treatment have abnormal levels of carnitine and have demonstrated a link between these abnormal levels and some dialysis-related conditions. This study will determine whether supplementation with L-carnitine is beneficial in the treatment of some clinical disorders experienced by haemodialysis patients.